Abstract
A 59-year-old male was diagnosed with nephrotic syndrome secondary to light-chain deposition disease. There was no other evidence of a B cell clonal disorder or amyloidosis; circulating free light chains were identified using a new immunoassay (Freelite) and used to monitor disease progression. Improvement in renal function and proteinuria following VAMP chemotherapy correlated with a reduction in circulating light-chain levels. This case demonstrates a new tool in monitoring light-chain deposition disease in the kidney.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Azathioprine / administration & dosage
-
Basement Membrane / metabolism
-
Basement Membrane / ultrastructure
-
Disease Progression
-
Humans
-
Hypergammaglobulinemia / blood
-
Hypergammaglobulinemia / diagnosis*
-
Hypergammaglobulinemia / drug therapy
-
Hypergammaglobulinemia / pathology
-
Immunoassay / methods*
-
Immunoglobulin kappa-Chains / blood*
-
Immunoglobulin lambda-Chains / blood*
-
Kidney / pathology
-
Kidney Tubules / metabolism
-
Kidney Tubules / ultrastructure
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Nephrotic Syndrome / etiology*
-
Prednisolone / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Immunoglobulin kappa-Chains
-
Immunoglobulin lambda-Chains
-
Vincristine
-
Prednisolone
-
Azathioprine
-
Methotrexate